Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Research & Development (2016 - 2025)

Cytokinetics (CYTK) has disclosed Research & Development for 16 consecutive years, with $170.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development changed N/A to $170.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $467.3 million, a N/A change, with the full-year FY2025 number at $416.0 million, up 22.57% from a year prior.
  • Research & Development was $170.2 million for Q4 2025 at Cytokinetics, up from $112.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $170.2 million in Q4 2025 to a low of $31.6 million in Q1 2021.
  • A 5-year average of $75.5 million and a median of $79.5 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 100.13% in 2021, then decreased 4.32% in 2024.
  • Cytokinetics' Research & Development stood at $43.5 million in 2021, then skyrocketed by 72.46% to $75.0 million in 2022, then rose by 13.27% to $85.0 million in 2023, then decreased by 0.43% to $84.6 million in 2024, then soared by 101.21% to $170.2 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Research & Development are $170.2 million (Q4 2025), $112.6 million (Q2 2025), and $99.8 million (Q1 2025).